Efficiency of BRCAPRO and Myriad II mutation probability thresholds versus cancer history criteria alone for BRCA1/2 mutation detection.

Familial Cancer
J J T van HarsselEncarna Gómez García

Abstract

Considerable differences exist amongst countries in the mutation probability methods and thresholds used to select patients for BRCA1/2 genetic screening. In order to assess the added value of mutation probability methods, we have retrospectively calculated the BRCAPRO and Myriad II probabilities in 306 probands who had previously been selected for DNA-analysis according to criteria based on familial history of cancer. DNA-analysis identified 52 mutations (16.9%) and 11 unclassified variants (UVs, 3.6%). Compared to cancer history, a threshold > or = 10% with BRCAPRO or with Myriad II excluded about 40% of the patients from analysis, including four with a mutation and probabilities <10% with both programs. All four probands had a BRCA2 mutation. BRCAPRO and Myriad II showed similar specificity at 10% threshold, overall BRCAPRO was more sensitive than Myriad II for the detection of mutations. Only two of the probands with an UV had probabilities >20% with BRCAPRO and Myriad II. In summary, BRCAPRO and Myriad II are more efficient than cancer history alone to exclude patients without a mutation. BRCAPRO performs better for the detection of BRCA1 mutations than of BRCA2 mutations. The Myriad II scores provided no additional inform...Continue Reading

References

May 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
May 15, 1997·The New England Journal of Medicine·F J CouchB L Weber
Oct 23, 1997·JAMA : the Journal of the American Medical Association·D Shattuck-EidensA Thomas
Mar 7, 1998·American Journal of Human Genetics·G ParmigianiO Aguilar
Jul 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T S FrankA Thomas
Feb 15, 2001·American Journal of Human Genetics·D ThompsonUNKNOWN Breast Cancer Linkage Consortium
Mar 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas S FrankGregory C Critchfield
Jun 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Donald A BerryGiovanni Parmigiani
Apr 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·UNKNOWN American Society of Clinical Oncology
Oct 25, 2003·Science·Mary-Claire KingUNKNOWN New York Breast Cancer Study Group
Sep 24, 2004·British Journal of Cancer·A C AntoniouD F Easton
Apr 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Encarna B Gómez-GarcíaArthur van den Wijngaard
Feb 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paul A JamesClare Scott
Feb 21, 2006·Cancer Research·Georgia Chenevix-TrenchUNKNOWN kConFab Investigators
May 3, 2008·Cancer Research·Daniel J FarrugiaFergus J Couch
Feb 10, 2009·Breast Cancer Research : BCR·Encarna B Gómez GarcíaMaaike P G Vreeswijk

❮ Previous
Next ❯

Citations

Mar 23, 2012·Breast Cancer Research and Treatment·Eunyoung KangUNKNOWN Korean Breast Cancer Society
Aug 28, 2012·International Journal of Oncology·Srdjan NovakovićAleš Vakselj
Mar 28, 2013·Surgical Neurology International·George StranjalisDamianos E Sakas

❮ Previous
Next ❯

Software Mentioned

CaGene
SPSS
BRCAPRO
BOADICEA
CancerGene

Related Concepts

Related Feeds

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.